QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

$228.74
0.00 (0.00%)
(As of 01/9/2024)
Today's Range
$228.74
$228.74
50-Day Range
$228.74
$228.74
52-Week Range
$123.77
$228.96
Volume
86 shs
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$210.45

Seagen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
8.0% Downside
$210.45 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.63
Upright™ Environmental Score
News Sentiment
0.00mentions of Seagen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.82) to ($1.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.38 out of 5 stars

Medical Sector

884th out of 934 stocks

Biotechnology Industry

21st out of 24 stocks


SGEN stock logo

About Seagen Stock (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

SGEN Stock Price History

SGEN Stock News Headlines

MRNA Feb 2024 67.000 put
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Seagen (NASDAQ:SGEN) Now Covered by StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
SGEN Jan 2024 210.000 put
SGEN Jan 2024 235.000 put(CONTR
SGEN Dec 2023 195.000 put(CONTR
HBM Gets Health Boost From Drug Licensing Deals
What the Options Market Tells Us About Seagen
A Closer Look at Seagen's Options Market Dynamics
Seagen: HER2CLIMB-02 Study Results Reinforce Clinical Activity Of TUKYSA
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$210.45
High Stock Price Target
$229.00
Low Stock Price Target
$129.00
Potential Upside/Downside
-8.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-32.12%

Debt

Sales & Book Value

Annual Sales
$2.30 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
Optionable
Beta
0.32

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy Seagen Stock? SGEN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Seagen was last updated on Friday, February 16, 2024 at 11:50 AM.

Pros

Here are some ways that investors could benefit from investing in Seagen Inc.:

  • Seagen Inc. is a biotechnology company that develops and commercializes therapies for the treatment of cancer.
  • Seagen Inc. operates both in the United States and internationally, providing potential for global market expansion.
  • Recent developments in cancer treatment have increased the demand for innovative therapies, which Seagen Inc. specializes in.
  • Seagen Inc. has a strong track record of research and development, with a focus on cutting-edge technologies and advancements in cancer treatment.
  • As of the latest update, Seagen Inc. is a subsidiary of Pfizer Inc., which brings additional resources and expertise to support its growth.

Cons

Investors should be bearish about investing in Seagen Inc. for these reasons:

  • Investing in biotechnology companies carries inherent risks, including clinical trial failures and regulatory challenges.
  • The competitive landscape in the cancer treatment market is intense, with other established players and emerging startups vying for market share.
  • Fluctuations in healthcare policies and regulations can impact the pricing and reimbursement of cancer therapies, affecting Seagen Inc.'s financial performance.
  • Market volatility and economic uncertainties can influence investor sentiment towards the biotechnology sector, including Seagen Inc.
  • It is important for investors to carefully evaluate Seagen Inc.'s financials, including revenue growth, profitability, and cash flow, to make informed investment decisions.














SGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price target for 2024?

12 equities research analysts have issued 1-year price objectives for Seagen's shares. Their SGEN share price targets range from $129.00 to $229.00. On average, they anticipate the company's stock price to reach $210.45 in the next twelve months. This suggests that the stock has a possible downside of 8.0%.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2024?

Seagen's stock was trading at $228.74 at the start of the year. Since then, SGEN shares have increased by 0.0% and is now trading at $228.74.
View the best growth stocks for 2024 here
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The biotechnology company had revenue of $648.65 million for the quarter, compared to analysts' expectations of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. Seagen's revenue was up 27.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.03) EPS.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of institutional and retail investors. Top institutional investors include Clear Street Markets LLC (0.00%), Public Sector Pension Investment Board (0.00%), Mint Tower Capital Management B.V. (0.00%), Neuberger Berman Group LLC (0.00%), Cowen AND Company LLC (0.00%) and Segantii Capital Management Ltd (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
This page (NASDAQ:SGEN) was last updated on 2/22/2024 by MarketBeat.com Staff